Cardiol Therapeutics (CRDL) Operating Expenses (2020 - 2026)

Cardiol Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 20.49% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $25.8 million (down 11.28% YoY), and the FY2025 full-year result was $24.6 million, down 14.65% from the prior year.
• Operating Expenses for Q1 2026 stood at $7.1 million, up from $5.8 million in the prior quarter.
• The five-year high for Operating Expenses was $10.4 million in Q3 2024, with the low at $4.7 million in Q2 2023.
• Historically, Operating Expenses has averaged $6.8 million across 5 years, with a median of $6.2 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses tumbled 43.66% — and 2024, when it surged 81.51%.
• Cardiol Therapeutics' Operating Expenses stood at $6.7 million in 2022, then slipped by 11.98% to $5.9 million in 2023, then increased by 21.25% to $7.2 million in 2024, then slipped by 19.47% to $5.8 million in 2025, then increased by 22.91% to $7.1 million in 2026.
• The last three Operating Expenses figures came in at $7.1 million (Q1 2026), $5.8 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.